Prevention of polymorphic light eruption with a sunscreen of very high protection level against UVB and UVA radiation under standardized photodiagnostic conditions.
Polymorphic light eruption (PLE), with an overall prevalence of 10-20%, is mainly provoked by ultraviolet A (UVA) (320-400 nm) and to a lesser degree by UVB (280-320 nm). The most effective prophylaxis of PLE, application of UV protection clothing, is not feasible for all sun-exposed areas of the skin and UV-hardening is time-consuming and may be associated with side-effects. Most sunscreens protect predominantly against UVB and therefore fail to prevent PLE. The protection level of potent UVA-protective filters remains unresolved. This single-centre, open, placebo-controlled, intra-individual, comparative study, analysed the efficacy of a sunscreen of very high protection level against UVB and UVA, containing methylene bis-benzotriazolyl tetramethylbutylphenol (Tinosorb M), bis-ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S) and butyl methoxydibenzoylmethane as UVA absorbing filters, in the prevention of PLE under standardized photodiagnostic conditions. After determination of the minimal erythema dose at day 0, photoprovocation was performed in 12 patients with a clinical history of PLE, on days 1, 2 and 3 with 100 J/cm2 UVA and variable doses of UVB, starting with the 1.5-fold minimal erythema dose of UVB. Prior to irradiation, placebo was applied to the right and sunscreen to the left dorsal forearm under COLIPA (European Cosmetic, Toiletry and Perfumery Association) conditions. In 10 patients PLE could be provoked at the placebo site, with positive reactions in 90% of the UVA, 40% of the UVB and 90% of the UVA/UVB irradiated fields. At the site with the active treatment none of these patients developed PLE. These data demonstrate that a sunscreen with effective filters against UVA and UVB can successfully prevent the development of PLE. Further studies are needed to examine whether regular application of sunscreen under everyday conditions, especially in doses less than the tested COLIPA-norm, could be an equivalent alternative to UV-hardening therapy.
Schleyer
Verena
V
Dermatology Clinic, Augsburg, Germany.
Weber
Oliver
O
Yazdi
Amir
A
Benedix
Frauke
F
Dietz
Klaus
K
Röcken
Martin
M
Berneburg
Mark
M
D000473:Alkanes / Q000032:analysis / Q000627:therapeutic use; D047188:Chalcones / Q000032:analysis / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000032:analysis / Q000627:therapeutic use; D010787:Photosensitivity Disorders / Q000517:prevention & control*; D011427:Propiophenones; D013473:Sunscreening Agents / Q000737:chemistry / Q000627:therapeutic use*; D014227:Triazines / Q000032:analysis / Q000627:therapeutic use; D014466:Ultraviolet Rays / Q000009:adverse effects*
D000473:Alkanes; D047188:Chalcones; D010636:Phenols; D011427:Propiophenones; D013473:Sunscreening Agents; D014227:Triazines; C500403:methylene bis-benzotriazolyl tetramethylphenol; C049935:avobenzone; C439083:bis-ethylhexyloxyphenol methoxyphenyl triazine